Source: Eur Respir J 2001; 18: 316-322
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Dequin P-F., Faurisson F., Lemarie E., Delatour F., Marchand S., Valat C., Boissinot E., de Gialluly C., Diot P.. Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis. Eur Respir J 2001; 18: 316-322

Member's Comments

No comment yet.

Related content which might interest you: Long-term clearance from small airways in patients with cystic fibrosis Source: Eur Respir J 2005; 25: 317-323 Year: 2005 Lung function parameters influence serum concentration after antibiotic inhalation in patients with cystic fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 537s Year: 2001 Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis Source: Eur Respir J 2002; 20: 122-126 Year: 2002 Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis Source: Eur Respir J 2002; 19: 294-302 Year: 2002 Absorptive clearance of DTPA as an aerosol-based biomarker in the cystic fibrosis airway Source: Eur Respir J 2010; 35: 781-786 Year: 2010 Functional respiratory imaging assessment of the aerosol deposition of inhaled levofloxacin in cystic fibrosis lungs Source: Virtual Congress 2021 – Cystic fibrosis Year: 2021 The assesment of aerosol solution lung deposition in cystic fibrosis patients Source: Eur Respir J 2004; 24: Suppl. 48, 584s Year: 2004 Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung Source: Eur Respir J 2016; 47:1392-1401 Year: 2016 Once-daily tobramycin in the treatment of adult patients with cystic fibrosis Source: Eur Respir J 2002; 19: 303-309 Year: 2002 Long-term administration of aerosolised tobramycin in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 619s Year: 2005 Nebulised 7 % hypertonic sodium chloride improves lung function and airway clearance in non cystic fibrosis bronchiectasis Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010 Effect of high dose tobramicin (TOBI®) inhalation on respiratory values in cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 503s Year: 2003 Possible mechanisms of action of azithromycin in cystic fibrosis Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005 Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Emerging pathogens in cystic fibrosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=66 Year: 2006 Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency Source: Eur Respir J 2009; 33: 354-360 Year: 2009 Inhalation therapy in cystic fibrosis Source: School Course 2013 - Cystic Fibrosis Year: 2013